Healthcare Insurance CEO Joins Intersect ENT’s Board of Directors

Intersect ENT Inc. has appointed Teresa (Terri) L. Kline to the company’s board of directors effective Aug. 1. Current director Casey Tansey, general partner of U.S. Venture Partners (USVP), will step down from the board following more than a decade of service.
 
Kline is a leader in healthcare insurance, managed care, physician practice management, and outpatient facility management. As president and CEO of Health Alliance Plan (HAP), a Michigan-based nonprofit health plan providing coverage to nearly 700,000 members, Kline provides strategic, financial, and operational leadership for the organization and its five subsidiaries. She is also an executive vice president of Henry Ford Health System, which is comprised of hospitals, medical centers and one of the nation’s largest group practices, the Henry Ford Medical Group.
 
“We are thrilled to welcome an advisor of Terri’s caliber to our board. With a career in health care leadership spanning 30 years, her deep provider and payer expertise will be invaluable as we deliver on our commitment to ensuring patients and physicians have access to our technologies,” said Lisa Earnhardt, president and CEO of Intersect ENT.
 
“I have admired Intersect ENT for its products, leadership team, and dedication to advancing care for patients, and I’m honored to be joining the company’s board,” said Kline. “I look forward to working with Lisa and with my fellow board members to help realize all of Intersect ENT’s potential.”
 
Kline’s knowledge of healthcare market dynamics and regulations has enabled her to balance patient, physician, employer, and payer needs throughout her career. Prior to her current role, she served as senior vice president and chief health care management officer for Health Care Service Corporation (HCSC), senior vice president of HealthSouth, CEO of United Healthcare of Georgia, and regional vice president of Aetna Health Plans. Kline also serves on the board of directors of Presbyterian Health Plan in New Mexico. She holds a bachelor’s degree in biology from Kalamazoo College and a master of public health degree from the University of Michigan.

Tansey’s relationship with Intersect ENT dates back to 2006, when he joined the board as the representative of USVP in connection with the firm’s participation in Intersect ENT’s Series A funding.
 
“It’s been rewarding to watch Intersect ENT emerge as one of the most exciting medtech companies in the world. Working with Lisa and the rest of my fellow board members has been a great privilege,” said Tansey. “At USVP we believe in the disruptive power of innovation and understand that great teams, working together, can accomplish amazing things. We’ve seen that first hand at Intersect ENT.”
 
“We thank Casey for his many years of invaluable service and support,” said Earnhardt. “He has been a trusted partner and advisor every step of the way for over a decade. We wish him and the USVP team continued success.”
 
Intersect ENT is dedicated to transforming the landscape of care for patients with ear, nose and throat conditions. The Menlo Park, Calif.-based company’s PROPEL family of dissolvable steroid releasing sinus implants are clinically proven to improve outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost effective care.